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Abstract 
The purpose of this manuscript is to discuss relevant aspects of clinical trials for Systemic 
Sclerosis (SSc) and to identify important considerations for the design of SSc disease 
modification clinical trials. Placebo randomized controlled trials with appropriate identification 
of SSc patients with diffuse progressive SSc skin involvement of recent onset, along with a 
rescue strategy for patients with worsening lung and skin involvement are suggested. If change 
in skin thickening is a major outcome of the study, the selection of patients with recent onset of 
disease and a predetermined degree of skin involvement are crucial requirements. The trial 
duration should be of at least 12 months. Sample size calculations should consider differences 
that exceed the Minimal Important Difference. Other relevant trial designs and potential threats 
to study validity are also discussed. Previous SSc-disease modifying trials have been beset by 
high dropout rates.  Analyses on the subset of subjects completing the trial or applying the last-
observation-carried-forward approach can potentially lead to biased estimates and false 
conclusions. Strategies for retention of subjects should be included at the design stage and 
analyses to account for missing data should be performed.
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Significance and Innovation 
• There is an urgent unmet need for the development of effective disease modifying 
therapies for Systemic Sclerosis (SSc). 
• Most disease modification SSc clinical trials have failed to identify effective disease 
modifying therapeutic interventions. 
• During the design phase of the study, predictors of disease worsening should be identified 
based on knowledge of the natural history of the organ system under study.  Predictors 
should be considered during both the design and analysis phases of the study.  
• Important considerations relevant to trial design are discussed and evaluated with the goal 
of enhancing clinical research to identify effective disease modifying therapies for SSc. 
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Introduction 
Since the first description of scleroderma treatment by Carlos Curzio in 1753 which 
included warm milk and vapor baths, bleeding from the foot, and oral administration of small 
doses of quicksilver (1), until the most recent clinical trials of anti-TGF-β monoclonal antibodies 
and novel tyrosine kinase inhibitors (2-10), numerous medications have been employed for 
treating this condition. Despite intense efforts to develop effective therapies, systemic sclerosis 
(SSc) remains as the autoimmune rheumatic disease with the highest case-specific mortality. 
Furthermore, there is a general perception that no disease modifying therapeutic modalities are 
available and that any therapeutic approaches currently employed are clinically ineffective. 
Although numerous therapeutic agents have been suggested to be effective in uncontrolled 
clinical trials or in descriptive unblinded studies rigorous evaluation failed to confirm these 
suggestions.   
The relative rarity of SSc, its clinical heterogeneity and the lack of quantitative and 
unbiased assessment tools to evaluate the effectiveness of therapeutic interventions have 
imposed serious limitations to the design and performance of informative clinical trials in this 
disease. Based on different pathophysiological concepts, diverse trial design approaches have 
been used to develop phase 1 and phase 2 trials for potential SSc disease modifying drugs (11).  
Despite these efforts, effective treatments for SSc remain elusive with no clear and widely 
accepted standard for treating its broad spectrum of clinical manifestations. The paucity of data 
showing effective disease modifying therapeutic interventions for SSc, our best wishes to help 
patients with this disease and the clamorous necessity for effective therapies, coupled with the 
expected increase of new trials in the near future render the limitations in the performance of 
controlled clinical trials an unavoidable obstacle that must be surmounted. Consequently, we will 
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focus this review towards establishing a framework and describing an approach to the design and 
development of disease modifying SSc clinical trials that may be useful for investigators 
designing and engaging in such trials. 
It is important to emphasize that cutaneous SSc involvement constitutes a specific subset 
of the broad disease spectrum and that paradigms and clinical response expectations for other 
manifestations of the disease, such as pulmonary artery hypertension or SSc-related interstitial 
lung disease (ILD) should not be directly extrapolated from the observations related to skin 
involvement. 
We are aware that satisfying all clinical trial requirements in terms of statistical 
correctness, ethical perspective and feasibility will be difficult for SSc disease modification 
trials. Thus, recognizing that it will not be possible to design a universally acceptable fixed 
clinical trial design, it is our purpose to discuss several crucial aspects of trial design that will 
need to be considered and addressed in the design of future SSc disease modification clinical 
trials. 
 
Randomized Controlled Trials vs Single-Arm Open Label trials 
Single-arm open label trials are used to obtain preliminary data regarding the safety of a 
drug and may help to develop and refine the parameters for the outcome variables to be 
evaluated. In any single arm trial, observed improvements may not be attributable to study 
treatment.  For example, if the outcome of interest is not an objective measure, both physicians 
and patients may believe they observe improvement that is not genuine.  Measures based on rater 
interpretation, such as the modified Rodnan Skin Score (mRSS) or visual analog scales (VAS), 
are vulnerable to this type of observation bias.  Another possible explanation for observed 
improvements not related to the study treatment could be the natural course of the disease. For 
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example, skin will soften spontaneously in some SSc patients. On the other hand, disease course 
could also obfuscate a positive treatment effect; patients may show no improvement during the 
trial, but disease would have progressed in the absence of the study treatment.  In SSc, the 
heterogeneous clinical presentation and the variability in the natural course of the disease render 
single arm studies of limited value to explore effectiveness of any potential therapeutic agent. To 
illustrate how the variable course of the disease can affect treatment outcome, it should be 
remembered that Carlos Curzio’s treatment of the scleroderma patient he described resulted in 
softening of her skin after 11 months of therapy.  
The evaluation of safety data for a single arm trial can also lead to ambiguous findings. 
For a heterogeneous disease, such as SSc, that gives rise to a complex array of clinical 
manifestations impacting multiple organ systems, distinguishing adverse reactions related to the 
disease from those attributable to the therapeutic intervention can be a significant challenge. 
These considerations became quite apparent in a recent single-arm open study of imatinib 
mesylate in which it was extremely difficult to adjudicate with certainty numerous clinical 
manifestations to either the disease course or as adverse reactions to the therapeutic intervention 
(Robert Spiera, personal communication). However, it should be emphasized that there is an 
important role of single drug open label trials for the acquisition of preliminary information 
about safety as well as to obtain valuable mechanistic insights of the proposed intervention and 
to assist in the development and honing of outcome measures. Furthermore, these trials are 
substantially less difficult and less expensive to conduct since they have an easier recruitment 
and design.   
A well-designed blinded randomized controlled clinical trial (RCT) can overcome the 
weaknesses outlined above for the single-arm study.  In the discussion below, we review issues 
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associated with the design and analysis of RCTs as they apply to trials in SSc.  We attempt to 
maintain our recommendations consistent with published guidance documents from the Food and 
Drug Administration (FDA) and the International Conference on Harmonization (ICH), which 
provide principles and methodology to ensure that the assessments of efficacy and safety are 
unbiased and scientifically valid. 
 
Randomized Placebo Control Trials  
A key decision when designing a RCT is the choice of control group. Placebo-controlled 
trials are preferred when the objective is to assess efficacy and safety of the study treatment after 
accounting for the influences of disease course and physician or patient expectations.  Placebo-
controlled trials are considered ethical when no effective treatment is known or when the use of 
placebo does not expose the subjects to excessive risk of harm provided that subjects are 
informed of the risks. Even when use of placebo is deemed ethical, physicians and their patients 
may be reluctant to participate in a placebo-controlled study, which presents a problem for 
recruiting sufficient numbers of subjects for the trial. When use of placebo presents ethical or 
practical concerns, the study treatment can be compared to a prior existing therapy or standard of 
care.  When the control is an active therapy, the objective of the trial is to demonstrate either 
non-inferiority or superiority of the study treatment compared to the active control, the choice 
likely depending on the perceived effectiveness of the active control.  Regarding SSc, the most 
relevant question in this matter is whether there is an accepted standard of disease modifying 
treatment for these patients. 
Although SSc is characterized by broad multi-systemic organ involvement, the 
involvement of skin in SSc is almost universal and constitutes a specific subset of the broad 
disease spectrum.  At the present time, there is no universally accepted disease modifying 
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therapy for the cutaneous manifestations of the disease.  Only a few studies have demonstrated a 
statistically significant impact on the mRSS. In the study described by Tashkin et al. (12), 
subjects with SSc-associated lung disease treated with 1 year of oral cyclophosphamide had 
significant improvement in mRSS at 12 months compared to subjects receiving placebo. 
However, owing to its adverse event profile, cyclophosphamide is not a preferred treatment 
option for skin disease in the absence of interstitial lung disease (ILD).  
From the review of 8 RCT for diffuse skin disease in SSc, excluding trials for treatment 
of Raynaud’s phenomena and SSc-associated ILD (2-9), only one study showed a statistically 
significant difference between treated and control groups. This was a small trial (n=29) 
employing methotrexate (MTX) as a disease modifying drug, which showed a statistically 
significant improvement over placebo (p=0.03) at 24 weeks on a composite response variable 
(defined by improvement in mRSS, DLCO, or VAS for general well being).  The impact on 
mRSS alone was not significant (p=0.06) (5). The lack of significance of the effect on mRSS for 
this MTX trial and the failure of the other RCTs to find statistically significant treatment effects 
does not necessarily mean that all the treatments are ineffective.  A failed study may have 
included too few subjects to detect a meaningful clinical difference, or may have been too short 
in duration for the treatment to impact the pathologic effects of the disease on the skin, or biased 
in some way against the treatment.  For example, in a second RCT designed to evaluate MTX 
(n=71 randomized), analysis of 47 subjects who completed the study showed no statistical 
difference between MTX and placebo (8). A reanalysis of the data using a Bayesian approach 
and applying multiple imputations methods for missing data to reduce bias associated with loss 
of subjects suggested that subjects on MTX were more likely to have a favorable mRSS response 
than subjects on placebo. While this demonstrates that evaluation of a simple hypothesis 
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sometimes does not provide the entire picture and that a thoughtful analysis can glean 
information important to evaluating the full potential of a new therapy, the frequentist approach 
(i.e. hypothesis testing) is currently still the standard by which FDA will approve a drug for a 
labeling indication and by which clinical practice is changed.  The example of MTX for 
treatment of SSc skin manifestations illustrates the importance of overcoming design challenges 
in order to obtain unambiguous results.  
Another interesting example of a study that failed to find significant difference between 
treatment groups is the high dose versus low dose D-penicillamine trial (2). In this trial, a low 
dose of D-penicillamine was deemed by the investigators to be an appropriate control. Although 
this study has been widely quoted as supporting the concept that D-penicillamine is not an 
effective disease modifying therapy for SSc, this conclusion rests on the validity of the 
assumption that the low dose of D-penicillamine is not at a therapeutic or biologically active 
level. Recent research, however, demonstrating an extremely important role of extracellular 
matrix stiffness in the fibrotic process calls the validity of this assumption into question.  
Remarkable results from several recent studies (13-16) have shown that increased matrix 
stiffness resulting from lysyl oxydase 2 (LOX-2)-mediated cross-linking of collagen molecules 
and from interactions with specific integrins can result in a potent activation of profibrotic 
pathways and in increased production of collagen and other extracellular matrix proteins with 
worsening of the fibrotic process. These studies clearly indicate that disruption or blockage of 
collagen cross-linking would be expected to exert a potent antifibrotic effect. D-penicillamine is 
one of the most potent inhibitors of collagen cross-linking. These effects can last for prolonged 
periods of time depending on the turnover rates of the affected collagen molecules. Therefore, 
even very low doses of the drug may have quite potent anti-fibrotic effects mediated by the 
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modification of extracellular matrix stiffness.  Based on this new information, a more appropriate 
conclusion is that the high dose versus low dose D-penicillamine study was not able to 
differentiate between the two interventions or determine whether either intervention was 
effective or ineffective. As such, rejection of D-penicillamine as a potential disease modifying 
agent for SSc may have been premature.  
Given the absence of a universally accepted disease modifying treatment for skin 
manifestations, ethical concerns associated with designing a placebo controlled study are 
diminished.  Furthermore, placebo controlled trials are essential to establishing the absolute 
benefit of a new treatment over the natural course of disease.  Placebo-controlled trials, however, 
can be difficult to recruit especially with a disease like SSc where disease progression has 
serious and irreversible consequences.  Physicians are eager to offer SSc patients a disease 
modifying therapy, even one that is not proven or universally accepted, if there is a reasonable 
expectation of benefit. In addition, owing to anxiety about the future progression of their disease, 
patients are often unwilling to accept randomization to placebo, and if they do consent they may 
be quick to leave the study in the absence of perceived benefit.  Physician and patient reluctance 
to participate combined with the rarity of SSc can compromise the ability to complete an 
adequately powered blinded parallel-group placebo-controlled trial within a reasonable 
timeframe. 
To address this issue, use of historical controls as a comparator rather than placebo 
controls has been employed in some studies to describe the natural course of the disease. 
Generally, this approach will not produce comparable treatment groups, and hence bias is not 
adequately controlled, and subsequent findings are inconclusive.  While use of historical controls 
cannot be recommended in most situations, valid alternative placebo-controlled designs that 
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minimize exposure to placebo and/or provide a potentially active treatment to all subjects are 
worth consideration at the protocol development stage.  
Since no single design will be satisfactory in all situations, several alternative placebo-
controlled designs options are discussed below. Some are standard and well-known, others are 
progressive designs developed for trials in diseases other than SSc, but all should be considered 
for their potential to offer a way forward for clinical research on treatments for SSc.  Among 
several alternative designs outlined in the 2001 FDA guidance on choice of controls, “add-on”, 
“early escape”, and “randomized withdrawal” designs are some standard options that might be 
considered for SSc trials (17). Each has advantages and disadvantages. 
Add-on Design 
For the add-on design, all subjects are randomized to either study treatment or placebo in 
combination with a background therapy on which all subjects are maintained. The background 
therapy would typically be a “standard of care”.  If no proven or uniformly accepted standard of 
care therapy is available, a control therapy with reasonable expectation of benefit (e.g. MTX for 
cutaneous disease) might be appropriate given certain limitations (noted below). The advantage 
of this design is that all patients will receive some form of treatment, which might make the trial 
more acceptable to physicians and patients and easier to recruit, but there are several 
considerations. First, the effect of study drug alone cannot be assessed. If the combination of 
background-plus-study treatment proves to be better than background-plus-placebo, no definitive 
conclusions can be drawn about how the study treatment would fare as a monotherapy. Second, 
if the background therapy is effective, then it might be reasonable to assume that the difference 
between the background-plus-study treatment combination and background-plus-placebo 
combination would be smaller than the difference between study drug and placebo in the absence 
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of background therapy.  Under this assumption, the add-on study would need to be larger than 
the parallel-group placebo-controlled trial to achieve the same level of power.  Third, if the 
effectiveness of the control is not proven (e.g. MTX for cutaneous disease), and a clinically 
significant difference between groups is not detected, the study will be inconclusive i.e. both 
drugs might or might not be effective. Finally, this design is likely to be most useful in cases 
where the background and study therapies have different mechanisms of action, but the protocol 
development team should also be cognizant of potential adverse interactions between the 
therapies. 
Early Escape Design 
 In the early escape design, randomized treatment (placebo or study treatment) is 
discontinued if the disease worsens or doesn’t improve by a pre-specified point in time. The 
advantage of this design is that subject exposure to an ineffective treatment is minimized.  
Responder status or time-to-failure endpoints are the most appropriate for this design.  Since the 
consequences of SSc progression can be severe and irreversible, close monitoring for disease 
progression and implementation of plans for rescue therapy are necessary in every study on 
ethical grounds. However, it is important to recognize the limitations that institute of rescue 
therapy could pose on analysis of quantitative endpoints (see discussion below on Patient 
selection challenges and risk of progression). 
Randomized withdrawal 
 In the randomized withdrawal trial, all subjects receive study drug during an open label 
phase of the study. Subjects who respond during the open-label phase are randomized to either 
stay on study treatment or withdraw.  For example, SSc patients could be treated with open label 
study treatment for a predetermined period, for example of 9 months. After this period subjects 
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whose mRSS have remained stable or improved could be randomized to either stay on study 
treatment or withdraw. After another period of observation which would be of 6-9 months, if the 
subjects who remained on study treatment had significantly better improvement in mRSS than 
those who were withdrawn, the study treatment would be considered effective.  One important 
consideration in this design is that if the effect of the study treatment is expected to continue on 
after withdrawal, then the observation period will have to be long enough to witness 
deterioration of the response in order to observe differences between study arms.  Another 
consideration is that study treatment should be tapered slowly to minimize the risk of disease 
exacerbation associated with rapid withdrawal. A limitation of this design is that only the subset 
of the population that had a favorable response is included in the randomized portion of the 
study, so estimated treatment effects cannot be generalized to the population as a whole.  
 Over the last decade some innovative designs have been developed to improve efficiency, 
enhance recruitment, and address the ethical issue of equipoise when prior studies suggest a 
reasonable expectation of benefit. Some of these designs include the following: Three-stage 
design (18,19). Response Conditional cross-over (20), Placebo-phase design (21), and various 
Response-adaptive designs (22). These designs can allow smaller numbers of subjects required 
for the study, as well as, a reduction in the number of subjects in the placebo arm and have been 
successfully employed in studies of rare diseases. However, the relatively slow development of 
skin induration changes in SSc necessary to cause a meaningful modification of the mRSS as an 
outcome measure, the potential carry over effect of previous interventions, and the prolonged 
duration of disease modifying interventions for SSc may limit the potential application of these 
designs for SSc clinical trials. 
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Randomized Active Controlled Trials 
In situations where an effective therapy is available, a placebo-controlled trial may no 
longer be ethical. In SSc, some of the target organ manifestations such as renal crisis and 
pulmonary hypertension have highly effective therapy options. Marginal efficacy of 
cyclophosphamide has also been demonstrated in SSc-associated ILD.  If available, an active 
control should be considered for randomized clinical trials when failure to treat could result in 
life threatening consequences or significant morbidity.  For example, the currently ongoing 
autologous stem cell transplantation SCOT trial (and its mirror European study, ASTIS) use 
cyclophosphamide as an active control. Results of these trials are not known at present. It should 
be pointed out that in these two trials, the aggressive treatment scheme, the inclusion of patients 
with SSc-related alveolitis and the requirement of “life threatening disease” in their inclusion 
criteria clearly justify the use of a potent although potentially harmful active control. However, 
the well documented lack of durable effects of cyclophosphamide on SSc lung involvement and 
the substantial frequency of severe side effects suggest great caution in the use of this drug as a 
comparator active control.  Obviously, standard therapy for other manifestations of the disease 
should be allowed in both groups. 
 
Patient selection challenges and risk of progression 
To mitigate effects of the variable clinical course of SSc, and owing to the paradigm that 
early interventions are crucial for an effective SSc therapy most of the recent trials have been 
focused on subpopulations of patients with recent onset disease. Recent onset disease has been 
defined in different ways. A cut-off point of 18 to 24 months from the appearance of the first 
non-Raynaud’s SSc-involvement has been utilized in some studies and seems reasonable. 
However, to provide greater homogeneity regarding the skin involvement it may be appropriate 
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to define the onset of the disease as the appearance of clinically detectable skin induration to 
avoid problems that may be introduced, for example, by the presence of gastrointestinal 
symptoms such as gastroesophageal reflux. Furthermore, if skin thickening is a major outcome 
of the study, patients should have a substantial degree of skin involvement at the time of 
recruitment.  For example, a requirement for subjects to have diffuse cutaneous SSc with mRSS 
>16 at enrollment will enable the study to demonstrate the effectiveness of the therapeutic 
intervention employing the currently available outcome tools.   
 Although the selection of recent onset and moderate to severe skin involvement is useful 
from the clinical and mechanistic perspective there is strong evidence to suggest that there is a 
substantial risk of rapid and even fatal disease progression in patients with rapidly progressive 
skin involvement, particularly related to worsening renal and pulmonary involvement (2-9). 
Given the substantial risk of potentially serious, irreversible or life-threatening consequences 
associated with severe disease progression, aggressive monitoring is required to detect rapid 
progression of skin disease, and to recognize early signs of renal disease or alveolitis. Criteria for 
use of salvage therapies for patients with worsening lung and skin involvement should be pre-
specified in the protocol and are strongly recommended. However, choosing the drugs for 
salvage is difficult and represents another point of controversy. The recently published 
recommendations from EULAR/EUSTAR for management of SSc may assist investigators in 
selection of appropriate salvage therapies. One difficulty is that with the exception of the use of 
ACE inhibitors for renal crisis there are no available data conclusively demonstrating that the use 
of any drug can decrease SSc mortality.  Pulmonary involvement has emerged as the most 
frequent cause of mortality in SSc, accounting currently for about 60% of all SSc-related deaths.  
Since cyclophosphamide has been shown to stabilize recent onset SSc-related alveolitis and ILD 
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(12), it is suggested as the rescue therapy for patients who develop clinically significant alveolitis 
and ILD.  For patients with rapidly progressing skin involvement indicative of a dangerous 
progression of disease, there is no clear choice of rescue therapy. Given the modest effects 
observed for MTX in two RCTs, and positive evidence from uncontrolled trials suggesting 
possible effectiveness of mycophenolate mofetil (23-28), one of these two agents may be 
appropriate choices. 
Although failure to provide appropriate salvage therapy in the event of severe disease 
progression would be unethical, implementation of this design feature poses significant 
challenges with respect to analysis of the data and interpretation of the study results. Whereas 
randomization helps to assure treatment groups are comparable at the start of the trial, salvage 
therapy, which will be implemented erratically and differentially across treatment arms, 
undermines comparability and weakens the ability of the trial to adequately assess the impact of 
study treatment on patient outcomes.  If the “need for salvage therapy” is a component of the 
primary endpoint (e.g. response failure or time to failure), the impact of bias could be minimal 
providing criteria for implementing salvage therapies are pre-specified, clearly and objectively 
defined, and implemented consistently. On the other hand, numeric endpoints, for example 
mRSS, may be highly sensitive to bias if the time point for the primary assessment is after some 
subjects have received salvage therapy.  Under this scenario, the potential for bias should be 
recognized during the design phase with strong consideration of (1) how often salvage therapy is 
likely to be needed in the population under study, (2) what baseline characteristics would be 
useful predictors of subjects who might go on to salvage, and, importantly, (3) how will the 
chosen salvage therapies impact the primary endpoint of interest.  Consider the example where 
the primary endpoint is mRSS at a given time point, and mycophenolate mofetil is chosen as the 
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salvage therapy for rapidly progressing skin disease.  Assuming that both study treatment and 
mycophenolate mofetil are effective in lowering the skin score, if salvage with mycophenolate 
mofetil is used more often in the placebo arm than in the study treatment arm, then the observed 
difference between placebo and study treatment arms will be smaller than would have been 
observed in the absence of the salvage therapy.  That is, the estimated effect will be biased 
against the study treatment and statistical significance will be more difficult to achieve.  Typical 
data analysis approaches including exclusion of subjects who have received salvage therapy, 
ignoring that some subjects have received salvage, and carrying forward the last observation 
prior to salvage will all yield biased results.  If baseline predictors of need for salvage are 
available, an alternative might be to consider primary endpoint data for subjects receiving 
salvage as missing, and apply pre-specified approaches for handling missing data (see discussion 
below).  Importantly, since no statistical technique can overcome the impact of bias with 
absolute certainty, the study development team should discuss the likely severity of the bias due 
to salvage and risk posed to valid inference.  If the risk is too high, alternative endpoints or 
designs should be considered. 
As noted above, criteria for implementing salvage therapies should be clearly and 
objectively defined, but these decisions are also challenging. For cutaneous disease, it is 
suggested that a change exceeding the Minimal Important Difference (MID) as it was defined 
based on several prior SSc clinical trials and described by Khanna et al. (29) should be utilized. 
Khanna et al. estimated that the MID for the mRSS improvement to be 3.2 to 5.3 (e.g. ~ 15-25% 
for an mRSS of 21), thus we suggest that a worsening of > 6 on the mRSS (e.g. ~30% worsening 
in skin involvement for a mRSS of 21) should trigger the institution of the salvage therapy arm. 
Similarly, for evaluation of pulmonary worsening and based on data from previous clinical trials 
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a 15% reduction in TLC or FVC accompanied by the demonstration of new onset of alveolitis or 
fibrotic lesions in a high resolution computerized axial tomography scan should indicate the 
institution of salvage therapy with cyclophosphamide.  Based on the above mentioned 
considerations, a RCT design (placebo vs study drug) with salvage therapy for patients with 
worsening SSc pulmonary and skin involvement is suggested as shown in Figure 1. 
Subjects meeting a criterion for salvage therapy should remain in the study and continue 
with all planned study procedures and assessments.  Furthermore, subjects and study personnel 
should generally remain blinded to the study treatment assignment after salvage therapy is 
instituted.  Per ICH E9 guidelines, breaking the blind for an individual subject should only be 
considered when management of patient care would vary depending on the treatment 
assignment. In contrast to these guidelines, however, an FDA guidance on safety reporting 
requirements that went into effect on March 2011 outlines different reporting requirements for 
study treatment and comparator arms, which results in unblinding the treatment assignment for 
any subject experiencing an unexpected serious adverse event. According to the new guidelines 
serious unexpected suspected adverse reactions (SUSARs), which by definition can only occur in 
the study treatment arm, are reported in an expedited manner, but serious unexpected adverse 
experiences occurring in the comparator arm are not to be reported on the expedited timeline. 
Since expedited reports for SUSARs are also sent to Institutional Review Boards, site personnel 
will be unblinded.  In a study with few unexpected serious adverse events, the impact of 
unblinding the treatment assignment on a few subjects may be minimal. However, the scientific 
validity of the study could be jeopardized if the fraction of unblinded treatment assignments 
becomes too large. Study teams should monitor this and consider consulting with the FDA on 
alternate reporting strategies should a concern arise. 
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Duration of the trial 
Owing to the slow turnover of collagen in the tissues, the trial requires a long observation 
period to detect clinically evident changes. For example, a recent study employing the tyrosine 
kinase inhibitor imatinib mesylate showed that improvement in mRSS was not detectable at 3 
months and that a statistically significant improvement was observed at 6 months of treatment 
which continued until the termination of the study at 12 months (10). The same pattern was 
observed in a recent retrospective trial with mycophenolate mofetil showing statistical 
differences compared with a historical cohort only after 6 months (28). Furthermore, our own 
analysis of a cohort of recent onset rapidly progressive SSc patients treated with mycophenolate 
mofetil showed worsening mRSS skin scores during the first 6 months of treatment which was 
followed by statistically significant improvement in mRSS in the subsequent 6 months of the 
trial (unpublished observations). Thus, based on the experience from these studies as well as 
from other studies a 12 month intervention phase would be required as the minimal duration for a 
meaningful trial. Follow up at the end of the intervention is also advisable either as a part of the 
trial itself or as a continued extension. 
 
Endpoints 
A comprehensive review of potential endpoints for the study of SSc is beyond the scope 
of this discussion, but would include a wide variety of time-to-event outcomes, responder 
definitions, quantitative measures associated with individual manifestations of the disease, 
quality of life measures, patient reported outcomes, and biomarkers.  One endpoint used almost 
universally in SSc clinical trials is the mRSS, the only validated clinical measure of changes in 
the extent and severity of skin involvement in SSc (30-32). The mRSS is an improvement over 
the original description of the skin score (30), in terms of practical application and reduction of 
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interobserver variability and standard deviation.  In a study of intra- and inter-rater variation in 
the assessment of the mRSS in a diverse population of SSc patients with both diffuse and limited 
disease of variable severity, the coefficient of inter-rater variation (i.e. a measure of agreement 
between raters) was estimated at 25%. In contrast, the intra-rater coefficient of variation (i.e. 
within rater agreement) was 12%.  These two findings taken together suggest that repeated 
mRSS assessments on an individual subject should be made by the same rater. If the mRSS is the 
primary endpoint for a longitudinal study, the logistics of retaining the same rater throughout the 
study should be considered by the protocol development team. 
A significant challenge has been to identify endpoints that describe disease progression 
across multiple organ systems. An example is “event-free survival” (EFS), an endpoint of key 
interest in both the SCOT and ASTIS trials, where events are defined as death or significant 
organ failure. A second example, also from the SCOT study, is a new global composite rank 
score (GCRS) that reflects each subject’s “order” relative to every other subject in the study 
based on the following hierarchy of component outcome variables: death, failure of EFS, change 
in FVC, change in SHAQ, and change in mRSS.  Although it has intuitive appeal, the GCRS will 
have to be evaluated to determine whether scores represent an accurate assessment of disease 
progression or improvement. 
The development of new outcome measures is a priority in SSc clinical research. With 
more precise, sensitive, and quantitative outcome measures, clinical trials with fewer individuals 
enrolled and of shorter duration will be achievable.  
 
Threats to Study Validity 
Drop-outs and Missing Data 
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High dropout rates have been observed in past trials on disease modifying therapy in SSc. 
For example, 50% of subjects were lost in the D-penicillamine trial and 20% in the bovine 
collagen trial (2,6).  Missing data due to subject withdrawal can result in biased estimates of the 
effect of the study treatment on both efficacy and safety endpoints and undermine the validity of 
study conclusions.  A comprehensive review of methods for prevention and handling of missing 
data in clinical trials has been recently published by the National Research Council (33). Only a 
few highlights from these recommendations are repeated in the discussion below.  
Importantly, statistical approaches to account for missing data in the analysis will always 
rely on unverifiable assumptions about the missing data mechanism. Hence, strategies designed 
to minimize missing data on key outcomes during the design and implementation phases of the 
study have more power to ensure study integrity than statistical techniques.  The protocol design 
team should consider reasons why subjects might withdraw prematurely and consider potentially 
mitigating study design features. For example, SSc subjects may withdraw prematurely due to 
intolerance to the study treatment, lack of perceived treatment effect, or inconvenience attributed 
to long follow-up times or too many visits. To address withdrawal due to tolerability issues, the 
study design might include flexible dosing or include a run-in period to ensure tolerability prior 
to randomization. Options to minimize dropouts due to lack of perceived treatment effect include 
implementation of salvage therapies or considering a design that minimizes exposure to 
ineffective treatment of offers active treatment to most or all subjects.  The problem of long 
follow-up times is challenging in SSc trials given the long time required to observe changes in 
fibrosis, but care should be taken to keep the number study visits to a minimum and avoid 
unnecessary data collection at each visit. While the study is actively following subjects, site 
personnel should be trained to understand the importance of working to keep subjects in the 
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study and to collect and report data.  Subjects who are withdrawn from treatment should still be 
encouraged to continue to return for study visits and data collection. Sites should be adequately 
compensated for these efforts as an incentive to maintain vigilance in these efforts. Finally, data 
managers should monitor and query sites for missing data on a routine basis. 
Despite best efforts, some degree of missing data will be present in nearly every trial.  A 
pre-specified analysis plan to evaluate the study objectives should include information on all 
randomized subjects.  This is consistent with the principles of an intent-to-treat (ITT) analysis 
and requires that missing data for randomized subjects that withdrew prior to assessment of the 
endpoint of interest be accounted for the analysis. This approach is in contrast to many published 
reports on SSc trials where analysis of data from “completers” is presented as the primary 
analysis. Analysis of completers is only unbiased in the rare situation where missing subject data 
is “missing completely at random” (MCAR), which means missingness is attributable to reasons 
completely unrelated to any study variable.  For example, data may be missing due to equipment 
failure or withdrawal of the subject due to an out-of-town transfer away from the study clinical 
facilities.  Furthermore, analysis of “completers” only also wastes valuable information that is 
available on withdrawn subjects.   
Many statistical analysis tools are currently available that reduce bias associated with 
missing data and make use of available information on withdrawn subjects.  These include single 
imputation methods, maximum likelihood, multiple imputation, Bayesian methods, and methods 
based on generalized estimating equations. The choice of method depends on assumptions 
regarding the missing data mechanism and underlying the methodology.  Single imputation 
methods such as last-observation-carried-forward (LOCF) are commonly applied in SSc trials 
but rely on the often unrealistic assumption that the observation at the time of withdrawal would 
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not change if measured later.  In the case where subjects outcomes are expected to worsen with 
time the LOCF approach can underestimate the treatment effect if a disproportionate number of 
subjects on placebo arm withdraw. Reasonable assumptions about missing data should be 
discussed with the study team prior to choosing the statistical approach. In addition, the team 
should consider baseline assessments and historical information that might be predictive of 
future withdrawal, which could be incorporated into the analytic plan. In particular, the skin 
thickness progression rate, which has been shown to be predict mortality and early internal organ 
involvement should be assessed at baseline for studies in diffuse SSc (34). Finally, sensitivity 
analyses are also important to assess the degree to which the estimated treatment effects rely on 
the assumptions. 
 
Inadequate power 
Another consequence of the premature withdrawal of subjects from a trial is that the 
subjects remaining are likely to be a subset of subjects with more stable disease or with greater 
improvement in disease who have not experienced intolerable toxicities.  This subset no longer 
represents the target population.  In addition, the outcome assessments in the placebo and study 
treatment arms are likely to be more similar than would have been expected if subjects had not 
withdrawn. As a consequence, statistical power for the test of the treatment effect is reduced.   
A secondary consequence is in the design of future studies. In building a rationale for 
sample size estimates for a new trial, statisticians turn to published trials to extract estimates of 
responder rates and/or mean outcomes for the comparator arm along with estimates of the 
standard deviation. Extreme outcome values are likely to be under-represented among 
“completers”, which will bias estimated means and tend to reduce standard deviations.  If the 
standard deviation estimate is too small, the resultant sample size estimate will also be too small.  
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Care must be taken when using estimates from a trial with a high dropout rate in order to ensure 
that the assumptions used in the design of a new trial are appropriate.    
In addition to ensuring estimates derived from prior studies are appropriate, several other 
factors can impact the validity of sample size/power estimates and can, if ignored, undermine the 
success of the trial. First, the statistical test on which the sample size/power estimate is based 
must be consistent with the objectives and design of the study as well as the analysis planned for 
the primary endpoint upon completion of the trial. Sample size and power needs for key 
secondary endpoints should also be considered. If the analysis methods underlying the sample 
size/power calculations are inconsistent with the methods planned for analysis, the study may be 
under-powered to detect the treatment effect of interest or over-powered and larger than 
necessary.  
Second, the goal in selecting the sample size is to ensure the study is adequately powered 
to detect a “clinically meaningful effect”. A “clinically meaningful effect” should not be 
confused with a “statistically significant effect”; a treatment group difference of ANY magnitude 
no matter how small can be statistically significant if the study is large enough. The objective is 
to design an efficient study that has a reasonable probability (i.e. power) of detecting a clinically 
meaningful difference between treatment groups should one in fact exist. Since there is not 
always consensus on the magnitude of the “clinically meaningful effect”; the protocol 
development team should consider this question during the design stage consulting literature and 
expert opinion as needed.  This question has been considered by investigators in the field for 
studies where mRSS is of interest.  A recent Delphi exercise showed that a reduction of at least 
35% from the baseline is necessary to consider the effect clinically relevant and statistically 
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significant (35). This estimate is more generous that the MID calculation discussed above, but it 
may represent a more desirable goal in patients with severe skin disease. 
Third, the adequately powered study must be feasible.  Too often, site investigators will 
over-estimate how many subjects can be randomized within a reasonable time frame, and a large 
study will ultimately fail due to insufficient recruitment.  Another ill-advised practice is choosing 
a feasible sample size first then selecting a “clinically significant effect” large enough to produce 
the desired sample size.  The danger in this practice is that if the treatment effect for a new drug 
is smaller than that used for planning but still worthy of clinical consideration, the study may 
have insufficient power to detect the effect.   Although compromise is often needed owing to 
limited resources, a better approach is to consider alternate design and endpoint options before 
making a final decision on how best to meet the study objectives.  
 
Translational Research Considerations 
Given the clamorous necessity for the development of new disease modifying drugs for 
SSc, every effort should be made to address the potential mechanism of action of the proposed 
intervention. Skin biopsies can provide invaluable information with a low risk for the patient. 
Since many of the intracellular pathways involved in the expression of the fibrotic phenotype are 
not well defined in the context of the natural course of the disease and depending on the 
intervention proposed, it is suggested that both placebo and treatment groups should undergo 
skin biopsies. Analysis of these skin biopsies will allow the development and validation of more 
sensitive outcomes and the testing of potential therapeutic interventions in a shorter time and 
with a smaller number of subjects. The identification of serum biomarkers of disease activity 
should also become a high priority. Cytokine and autoantibody profiles from SSc patient samples 
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are valuable sources for biomarker candidate selection and subsequent testing in SSc and healthy 
populations.  
Although the mRSS has been considered a validated outcome for SSc disease modifying 
trials, it is not quantitative and is prone to subjective variability. Therefore, substantial efforts 
should be devoted to the development and validation of more sensitive and quantitative tools 
such as, for example, quantification of ECM protein expression on skin biopsies before and after 
treatment (36) or novel approaches based on newer molecular technologies such as global gene 
expression analyses (37-39), proteomics (40), or kinomics (41). Proteomics, microarrays and 
kinomics are extremely powerful tools which have provided valuable mechanistic information, 
particularly in oncologic disorders, however, are still underused in SSc. Their inclusion in any 
SSc mechanistic studies will provide invaluable data to direct and guide future research in the 
field. 
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Figure 1. Schematic example of a SSc disease modification RCT design.  
 
Note that the trial includes salvage therapy arms for worsening skin involvement and 
deterioration of lung function caused by new onset alveolitis or progression of lung fibrosis. The 
study also includes a post-study follow up phase. 
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